Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MSH 2IA

X
Drug Profile

MSH 2IA

Alternative Names: MagSense® HER2 Imaging Agent; MSH-2IA

Latest Information Update: 21 Feb 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Imagion Biosystems
  • Class Contrast media; Diagnostic agents; Diagnostic conjugates; Ferric compounds; Growth factors; Imaging agents; Oxides; Radiopharmaceutical diagnostics
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HER2 positive breast cancer

Most Recent Events

  • 13 Dec 2023 Imagion Biosystems announces intention to file an IND application with the US FDA in Q1 2024
  • 13 Dec 2023 Efficacy and adverse events data from a phase-I IBI10103 trial in HER-2 positive breast cancer released byImagion Biosystems
  • 13 Dec 2023 Imagion Biosystems completes a phase-I IBI10103 trial in HER-2 positive breast cancer in Australia (unspecified route) (Imagion Biosystems pipeline, December 2023) (ACTRN12621000126819)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top